Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, plays a significant role in regulating appetite and food intake
What does the science say about the risks of GLP-1 for people with eating disorders
The Medicare demonstration project covers GLP1s for obesity with qualifying comorbidities, which include obstructive sleep apnea
For non-overweight patients considering GLP-1 therapy, understanding the clinical criteria your provider usesand what biomarker and genetic context might inform treatment decisionssupports more personalized, evidence-based care
It also aids energy levels , recovery, and overall wellbeing in ways that extend beyond the direct hormonal effects
Liraglutide Liraglutide requires daily injections but allows more precise dose adjustments